ATTOX

Attox is a biotechnology company developing a transformative platform for the delivery of therapeutic proteins into the interior of cells. By re-engineering bacterial toxins, such as the anthrax toxin, the company has created a system capable of translocating large, functional proteins across the endosomal membrane into the cytoplasm. This approach enables the targeting of intracellular pathways that are currently unreachable by conventional antibody-based therapies. Attox is primarily focused on oncology, leveraging its platform to deliver potent payloads that can selectively trigger cell death or modulate disease-driving proteins within cancer cells. The company's technology originated from the research of Dr. Roman Melnyk at The Hospital for Sick Children and the University of Toronto. Attox aims to expand the druggable proteome by providing a reliable method for biologics to access the intracellular environment.